
Masimo (MASI) Stock Forecast & Price Target
Masimo (MASI) Analyst Ratings
Bulls say
Masimo Corp's healthcare segment, a significant revenue driver, is experiencing growth due to increased demand for its core SET pulse oximetry business and advancements in monitoring technologies such as capnography and hemodynamics. The company anticipates recognizing $507 million in unrecognized contract revenue over the next year, reflecting a year-over-year increase of 17%, while projecting EBIT margins to expand steadily through 2028. Furthermore, Masimo's international market penetration and the promising growth expectations in advanced monitoring platforms are indicative of strong future revenue growth, supported by new product launches.
Bears say
Masimo Corp faces a negative outlook primarily due to the anticipated impact of tariffs, with forecasts suggesting a $16 million to $17 million hit in FY25 that could reduce operating margins by approximately 110 basis points. Additionally, there are numerous risks affecting the company's financial stability, including potential delays in new product rollouts, challenges in supply chain management, and increased competition within both its healthcare and non-healthcare segments. Furthermore, the recent downward revision of the revenue forecast for Q4 2025, coupled with pricing pressure and declining hospital demand for capital equipment, further complicates the company’s growth prospects and revenue generation capabilities.
This aggregate rating is based on analysts' research of Masimo and is not a guaranteed prediction by Public.com or investment advice.
Masimo (MASI) Analyst Forecast & Price Prediction
Start investing in Masimo (MASI)
Order type
Buy in
Order amount
Est. shares
0 shares